Skip to main content

Advertisement

SpringerLink
Log in

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The efficacy and safety of S-1/oxaliplatin (SOX) therapy in patients with recurrent adenocarcinoma of the uterine cervix were examined in a pilot study.

Patients and methods

S-1 was orally administered for 14 days at a dose of 80–120 mg/body/day to 7 patients with recurrent adenocarcinoma of the uterine cervix, with oxaliplatin being administered intravenously at a dose of 100 mg/m2 on day 1. Each therapy cycle was 21 days, and the patients received 6 cycles at most. The antitumor effect, adverse events, progression-free survival (PFS), and overall survival (OS) were investigated.

Results

The median age of the patients was 49 years. The antitumor effect was rated as a complete response in 2 patients, partial response in 2, and stable disease in 3. The overall response rate was 57.1 %, and the disease control rate was 100 %. Regarding hematological toxicities of grade 3 or more, leukopenia, neutropenia and thrombocytopenia occurred in 42.9, 28.6 and 14.3 %, respectively; regarding non-hematological toxicities, grade 3 rectovaginal fistula occurred in 14.3 %, as well as grade 2 fatigue in 14.3 % of the patients. The median PFS and OS were 5 months (range 3–9 months) and 7 months (range 4–43 months), respectively.

Conclusions

These results suggest that SOX therapy is useful for the treatment of recurrent adenocarcinoma of the uterine cervix, having a promising antitumor effect and minimal adverse effects. It was also suggested that SOX therapy may contribute to improving the prognosis for patients with adenocarcinoma of the uterine cervix.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sherman ME, Wang SS, Carreon J et al (2005) Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer 103:1258–1264

    Article  PubMed  Google Scholar 

  2. Hopkins MP, Morley GW (1991) A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 77:912–917

    PubMed  CAS  Google Scholar 

  3. Shingleton HM, Gore H, Bradley DH et al (1981) Adenocarcinoma of the cervix: I. Clinical evaluation and pathologic features. Am J Obstet Gynecol 139:799–814

    PubMed  CAS  Google Scholar 

  4. Fu YS, Reagan JW, Hsui JG et al (1982) Adenocarcinoma and mixed carcinoma of the cervix: a clinicopathologic study. Cancer 49:2560–2570

    Article  PubMed  CAS  Google Scholar 

  5. Berek JS, Hacker NF, Fu Y et al (1985) Adenocarcinoma of the uterine cervix: histlogic variables associated with lymph node metastasis and survival. Obstet Gynecol 65:46–52

    PubMed  CAS  Google Scholar 

  6. Moberg PJ, Einhorn N, Silfverswärd C et al (1986) Adenocarcinoma of the cervix. Cancer 57:407–410

    Article  PubMed  CAS  Google Scholar 

  7. Katsumata N, Hirai Y, Kamiura S et al (2011) Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol 22:1353–1357

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  8. Shirao K, Ohtsu A, Takada H et al (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355–2361

    Article  PubMed  CAS  Google Scholar 

  9. Yamada Y, Tahara M, Miya T et al (2008) Phase I/II study of oxaliplatin in combination with S-1 (SOX) as first-line therapy for metastatic colorectal cancer. Br J Cancer 98:1034–1038

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Sugiyama T, Nishida T, Hasuo Y et al (1998) Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol 69:130–136

    Article  PubMed  CAS  Google Scholar 

  11. Tabata T, Nishiura K, Yanoh K et al (2004) A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocacinoma of the cervix. Int J Clin Oncol 9:59–63

    Article  PubMed  CAS  Google Scholar 

  12. Curtin JP, Blessing JA, Webster KD et al (2001) Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 19:1275–1278

    PubMed  CAS  Google Scholar 

  13. Shoji T, Kumagai S, Yoshizaki A et al (2012) Efficacy of neoadjuvant chemotherapy followed by radical hysterectomy in locally advanced non-squamous carcinoma of the uterine cervix: a retrospective multicenter study of Tohoku Gynecologic Cancer Unit. Eur J Gynaecol Oncol 33:353–357

    PubMed  CAS  Google Scholar 

  14. Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  15. Shoji T, Takatori E, Omi H, et al. (2012) Neoadjuvant chemotherapy using platinum-based regimens for stage Ib2-II squamous cell carcinoma and non-squamous cell carcinoma of the cervix. Squamous cell carcinoma. In: Li X (ed) Croatia, pp 79–92

  16. Kim GM, Jeung HC, Rha SY et al (2012) A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 48:518–526

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None of the authors of this manuscript has any conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka, Iwate, 020-8505, Japan

    Eriko Takatori, Tadahiro Shoji, Yasuko Suga, Hanae Niinuma, Yuki Miura, Yoshitaka Kaido, Anna Takada, Masahiro Kagabu, Satoshi Takeuchi & Toru Sugiyama

Authors
  1. Eriko Takatori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadahiro Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuko Suga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanae Niinuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuki Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Kaido
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anna Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiro Kagabu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Satoshi Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toru Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadahiro Shoji.

About this article

Cite this article

Takatori, E., Shoji, T., Suga, Y. et al. A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix. Int J Clin Oncol 19, 336–340 (2014). https://doi.org/10.1007/s10147-013-0539-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-013-0539-4

Keywords

Search

Navigation